



# ESCMID Global

European Congress of Clinical Microbiology & Infectious Diseases

## Preliminary Programme

### Vienna, Austria

11-15 April 2025



<http://www.escmid.org/congress-events/escmid-global>

# Disclaimer & Dates

## Disclaimer

The following ESCMID Global 2025 scientific programme is preliminary only and does not represent the entirety of the ESCMID Global 2025 invited programme. Speakers and chairpersons will be added to sessions as they are confirmed.

Integrated symposia from industry partners will also be published once confirmed in the website section dedicated to sponsors.

The ESCMID Global 2025 scientific programme is expected to be finalised in March 2025.

---

## Present your research and be part of ESCMID Global!

ESCMID Global 2025 has become one of the most comprehensive and influential congresses in the field of infection and an exciting networking place bringing together > 18,000 colleagues from all over the world.

Share and discuss your research with colleagues from around the world.


---

## Congress registration

Registration for the ESCMID Global Conference is currently open. Early bird rates apply until 5th of February 2025. After the early bird period, standard and late registration options will be available. For full details on ticket pricing, including early bird, standard and late registration rates, please visit our website at <https://www.escmid.org/congress-events/escmid-global/registration-travel/registration/>

Registration Dates	Early (until 5 February 2025)	Standard (until 5 March 2025)	Late (from 6 March 2025)
--------------------	-------------------------------	-------------------------------	--------------------------

# Keynote Lectures



## Keynote Lecture

### **Defending against dengue: global epidemiology and strategies for prevention and control**

***Fernanda Castro-Boulos (Sao Paulo, Brazil)***

*Chairs:*

*TBA*

*TBA*

Dengue is one of the common viral vector-borne diseases today including persistent outbreaks in Asia and Latin America. Extensions into North America are currently signals of its global importance as global warming increases the likelihood of dengue spreading into regions previously unaffected. With new vaccines available, policy makers have difficult decisions to take in selecting the proper one for the population at risk. This keynote lecture aims to explore the geographic distribution, clinical presentation, treatment algorithms and potential utility of current



## Keynote Lecture

### **What genomics brought to the knowledge of tuberculosis, leprosy and buruli ulcer**

***Stewart Cole (Paris, France)***

*Chairs:*

*Emmanuelle Cambau (Paris, France)*

*TBA*

Tuberculosis, leprosy and Buruli ulcer are the three most common infectious diseases caused by the same family of mycobacteria: *Mycobacterium tuberculosis*, *Mycobacterium leprae*, and *Mycobacterium ulcerans*, respectively. Stewart Cole will discuss perspectives on the current knowledge of these three mycobacteria infectious diseases and how genomics played an integral role in transforming the diagnosis, treatment and prevention practices for these infectious diseases. His keynote will reflect much of his current research that builds the bridge between fundamental science and medicine.



## Keynote Lecture

### **Infections after solid organ transplantation: past, present and future**

***Jay Fishman (Boston, United States)***

*Chairs:*

*Nina Khanna (Basel, Switzerland)*

*TBA*

Solid organ transplantation has progressed by leaps and bounds over the last few years globally. Knowledge of infections after solid organ transplantation has also improved the standard-of-care protocols mitigating infection by including pre-transplant screening, prophylaxis and vaccination. Newer and more potent immunosuppressive regimens have led to decreased rejection while exposing them to the risk of infections. Jay Fishman will discuss the history of infection development after solid organ transplantation, the evolution of prophylactic/pre-emptive strategies, and the harmonisation of quantitative CMV PCRs and vaccination. This session also looks to the future, elucidating the exciting new technologies enabling clinics to provide more organs to patients.



#### Keynote Lecture

#### **HIV: from needle parks to injectables**

***Huldrych Günthard (Zurich, Switzerland)***

*Chairs:*

*Gülseren Özkaya Sahin (Lund, Sweden)*

*Mary Horgan (Dublin, Ireland)*

From the initial emergence of the epidemic in needle parks to recent breakthroughs in injectable treatments, this keynote session offers an in-depth exploration of the history of HIV-1. This keynote lecture will provide a comprehensive understanding of the HIV landscape including scientific advancements, societal responses and current medical interventions. Attendees will gain insights into the challenges faced by individuals and communities affected by HIV/AIDS, as well as the progress made in combating the disease through compelling narratives and historical perspectives.



#### Keynote Lecture

#### **Asia: an AMR hot zone**

***David L. Paterson (Singapore, Singapore)***

*Chairs:*

*Giulia De Angelis (Rome, Italy)*

*Robert Leo Skov (Copenhagen, Denmark)*

AMR is a global public health threat, especially in Asia where high population density, fewer antibiotic regulations and surveillance, poor sanitation and limited access to quality healthcare have resulted in a disproportionate number of deaths from drug-resistant infections. David Paterson is the Director of ADVANCED ID - a clinical trials network across over 20 Asian countries. This keynote lecture will give an overview of AMR in ASIA and review the results of the epidemiological study ACORN-HAI. Additionally, it will explore strategies for developing clinical AMR in the long term.



#### Keynote Lecture

#### **Infectious disease challenges in an ever-changing environment**

***Pamela Rendi-Wagner (Solna, Sweden)***

*Chairs:*

*Jacob Moran-Gilad (Beer Sheva, Israel)*

*TBA*

Since 2005, ECDC focused on improving lives in Europe and globally through sound science by working with the European Union and global partners to drive public health policy and practice. In 2025, the agency will celebrate its 20th birthday and be equipped with a new mandate; this is a good time to look ahead. As we move into the second quarter of the 21st Century, there is a need for proactive and anticipatory approaches to public health to identify and prepare for unknown future threats and seize opportunities to reduce the impact of infectious disease. In this keynote, the new ECDC Director will outline some of these threats, and novel activities/approaches by the establishing and coordinating an EU Health Task Force for rapid health interventions in the event of major outbreaks, and new frameworks for assessing EU countries' preparedness.



#### Keynote Lecture

#### **The new frontiers in antimicrobial stewardship**

***Karin Thursky (Carlton, Australia)***

*Chairs:*

*Jose Ramon Pano-Pardo (Zaragoza, Spain)*

*Jeroen Schouten (Nijmegen, Netherlands)*

Antimicrobial resistance (AMR) is a global threat according to the WHO and one of the strategies to reduce the burden of AMR on global public health is reducing unnecessary antibiotic usage. Karin Thursky is one of the pioneers in the field of antibiotic and antifungal therapy publishing various studies on the prudent use of antimicrobials. The aim of this keynote is to give an overview on ways to preserve the effectiveness of antibiotics as well as give perspectives on the future of AMR and the impact on modern medicine.

**Co-organised with: Dutch Committee on Antimicrobial Policy, UEMS Section of Infectious Diseases**



#### Keynote Lecture

#### **Tuberculosis: where are we now and where should we be**

***Guy Thwaites (Ho Chi Minh City, Vietnam)***

*Chairs:*

*Jon S. Friedland (London, United Kingdom)*

*Delia Goletti (Rome, Italy)*

Tuberculosis (TB) remains a pressing global health issue, exacerbated by the growing prevalence of drug-resistant strains, including multi-drug resistant TB. Clinical trials are needed to fill in the missing evidence for this life-threatening disease. This keynote lecture will review the current situation regarding TB treatment and highlight where the gaps are. Guy Thwaites will describe the need for new clinical trials concerning drugs for the optimal treatment of TB as well as the potential for host-directed therapies.



#### Keynote Lecture

#### ***Staphylococcus aureus* host-microbe interaction: ecology, disease, and vaccine development**

***Juliane Bubeck Wardenburg (St. Louis, United States)***

*Chairs:*

*Annelies Zinkernagel (Zurich, Switzerland)*

*Anna Norrby-Teglund (Huddinge, Sweden)*

*Staphylococcus aureus* can go unnoticed in the composition of human skin microflora. However, if this Gram-positive opportunistic pathogen enters the blood or respiratory tract of the host, *S. aureus* can cause serious infections like pneumonia and sepsis. In this keynote lecture, Juliane Bubeck Wardenburg will review the pathogenesis and virulence, focusing on the interaction between *S. aureus*'s alpha-toxin and the host's receptor ADAM-10. Additional topics on current treatments and vaccine development will be highlighted.

# 2-hour Symposia

## 2-hour Symposium

### **Tick-borne encephalitis: contemporary diagnosis and management**

#### **Chairs:**

*Joanna Zajkowska (Bialystok, Poland)*

*Dace Zadvaska (Riga, Latvia)*

#### **Tick-borne encephalitis: immune response and clinical experience**

*Sara Gredmark Russ (Stockholm, Sweden)*

#### **TBE immune responses and vaccine effectiveness**

*Karin Stiasny (Vienna, Austria)*

#### **NS1 antibodies: diagnostics and screening of seroprevalence of TBE virus infection**

*Gherhard Dobler (Munich, Germany)*

#### **Treatment for TBE: where do we stand?**

*Daniel Ruzek (Brno, Czech Republic)*

## 2-hour Symposium

### **Haemorrhagic viral infections**

#### **Chairs:**

*Önder Ergönül (Istanbul, Turkey)*

*TBA*

#### **Ebola and Marburg: success of evolving therapeutic strategies**

*Ian Crozier (Frederick, United States)*

#### **Jack in the box: re-emergence of Kyasanur Forest Disease in India**

*Kavitha Saravu (Manipal, India)*

#### **Crimean Congo Haemorrhagic Fever: newer insights into pathogenesis leading to new vaccines and therapeutics**

*TBA*

#### **Venezuelan Equine Encephalitis: impact of newer strategies for vector control**

*Carlos Seas (Lima, Peru)*

2-hour Symposium

**Tackling the emergence of dengue and other *Aedes*-borne diseases in Europe**

**Chairs:**

*Martin Grobusch (Amsterdam, Netherlands)*

*TBA*

**How dengue, chikungunya and zika virus disease became emerging threats to Europe**

*Céline Gossner (Stockholm, Sweden)*

**Surveillance of dengue in urbanised tropical regions**

*Junxiong Pang (Singapore, Singapore)*

**Mosquito surveillance and control: opportunities and challenges**

*TBA*

**Prospects for dengue, chikungunya and zika virus vaccines**

*TBA*

**Co-organised with: European Centre for Disease Prevention and Control (ECDC)**

2-hour Symposium

***Staphylococcus aureus*: Its expansion dynamics and interactions with its pals**

**Chairs:**

*Barbara C. Kahl (Munster, Germany)*

*TBA*

***S. aureus* and its special relationship to *S. epidermidis***

*Andreas Peschel (Tubingen, Germany)*

**The role of the *S. aureus* type VII secretion system in host-bacterial community interactions**

*TBA*

**How bacteriophages and pathogenicity islands drive the evolution of *S. aureus***

*John Chen (Singapore, Singapore)*

**Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)**



2-hour Symposium  
**Sepsis Global 2025**

**Chairs:**

*Willem Joost Wiersinga (Amsterdam, Netherlands)*

*Brigitte Lamy (Paris, France)*

**The ISF awardee and ESGBIES Young Investigator Award lectures**

*TBA*

**The WHO Global Maternal Sepsis Study**

*Carolina C Ribeiro-do-Valle (Campinas, Brazil)*

**Sepsis: a year in review**

*Sylvain Meylan (Lausanne, Switzerland)*

**How to design and implement a Sepsis National Action Plan (SNAP)**

*Erika Vlieghe (Antwerp, Belgium)*

**Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)**

2-hour Symposium  
**Barriers to TB/HIV elimination in low- and high-incidence settings**

**Chairs:**

*Daria Podlekareva (Copenhagen, Denmark)*

*Graeme Ayton Meintjes (Cape Town, South Africa)*

**HIV and TB epidemic: the storm hasn't subsided yet**

*Tetiana Koval (Poltava, Ukraine)*

**Approaches for latent and active TB screening in people living with HIV**

*Raimonda Matulionytė (Vilnius, Lithuania)*

**Integration of HIV and TB care to improve patient outcome in resource-limited settings**

*TBA*

**How researchers can influence policy and practice in HIV/TB care**

*Jens Lundgren (Copenhagen, Denmark)*

**Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), Euroguidelines in Central and Eastern Europe Network Group**



2-hour Symposium

**STIs: an ongoing crisis**

**Chairs:**

*TBA*

*Dagmar Heuer (Berlin, Germany)*

**STI treatment options are running out due to AMR**

*Magnus Unemo (Örebro, Sweden)*

**Genomic surveillance of *Neisseria gonorrhoeae* strains**

*Petra Wolffs (Maastricht, Netherlands)*

**Evolutionary insights into syphilis and *Treponema pallidum***

*Mathew A. Beale (Hinxton, United Kingdom)*

**Challenges in chlamydial STI infections**

*Cecile Bebear (Bordeaux, France)*

**Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie**

2-hour Symposium

**News in endocarditis care**

**Chairs:**

*Michele Bartoletti (Milan, Italy)*

*Pilar Retamar Gentil (Sevilla, Spain)*

**Endocarditis guidelines: what is new?**

*Siegbert Rieg (Freiburg, Germany)*

**Oral therapy and outpatient care**

*Laura Escolà-Vergé (Barcelona, Spain)*

**PK/PD aspects of endocarditis antibiotic therapy**

*Fekade Bruck Sime (Brisbane, Australia)*

**The endocarditis team: there is no way to work alone**

*Barbara Hasse (Zurich, Switzerland)*

**Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Sociedad Espanola de Infecciones Cardiovasculares (SEICAV)**

## 2-hour Symposium

### **AMR Surveillance in low resource countries: insights into clinical and policy translation**

#### **Chairs:**

*Rogier van Doorn (Hanoi, Vietnam)*

*Kwame Ohene Buabeng (Ho, Ghana)*

#### **New indicators in national monitoring and evaluation of AMR supported by improved data utilisation**

*Direk Limmathurotsakul (Bangkok, Thailand)*

#### **Interdisciplinary investigation of the drivers and burden of AMR in urinary tract infections**

*Stephen Mshana (Mwanza, Tanzania)*

#### **A clinically-oriented AMR surveillance network: case-based surveillance and implementation**

*Paul Turner (Siem Reap, Cambodia)*

#### **National prescribing guidelines based on AMR surveillance data**

*Vilada Chansamouth (Vientiane, Lao People's Democratic Republic)*

#### **Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)**

## 2-hour Symposium

### **Gram-positives, are they still going?**

#### **Chairs:**

*Erik Bathoorn (Groningen, Netherlands)*

*TBA*

#### **The vanco chronicles: enterococci's global journey**

*Guido Werner (Wernigerode, Germany)*

#### **Pitfall in susceptibility testing of Gram-positives**

*Helena Zemlickova (Prague, Czech Republic)*

#### **Drivers for daptomycin and linezolid resistance in Gram-positives**

*Glen Carter (Melbourne, Australia)*

#### **What is new in treatment against MDR Gram-positives?**

*Alex Soriano (Barcelona, Spain)*

2-hour Symposium

**Molecular epidemiology, resistance mechanisms and management of Gram-negative bacteria**

**Chairs :**

*Kyriaki Xanthopoulou (Cologne, Germany)*

*Agnes Sonnenwend (Pécs, Hungary)*

**Globally emerging resistance patterns of Enterobacterales**

*Sasheela Ponnambalan (Kuala Lumpur, Malaysia)*

**Non-fermenters still important globally: a review of spread and resistance**

*Anupa Thampy (Vellore, India)*

**Innovative rapid diagnostic methodologies for Gram-negative pathogens**

*Laurent Dortet (Le Kremlin-Bicêtre, France)*

**Tailoring treatment to resistant Gram-negative bacteria: newer therapeutic approaches**

*Maria Milagro Montero (Barcelona, Spain)*

**Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)**

2-hour Symposium

**Using mathematical and epidemiological models to identify the drivers of AMR**

**Chairs:**

*Sarah Tschudin Sutter (Basel, Switzerland)*

*Marc Bonten (Utrecht, Netherlands)*

**Quantifying the drivers of antiviral resistance: what does it take to prevent resistance?**

*Roger Kouyos (Zurich, Switzerland)*

**Inferring the determinants of AMR dynamics across bacterial pathogens**

*Lulla Opatowski (Paris, France)*

**Expanding access to antibiotics with stewardship: a One Health perspective**

*TBA*

**Assessing the impact of microbiome dynamics on AMR evolution**

*TBA*

## 2-hour Symposium

### **Biomarker testing to manage respiratory infections in primary care in low resource settings**

#### **Chairs:**

*Heiman Wertheim (Nijmegen, Netherlands)*

*Sonia Lewycka (Hanoi, Viet Nam)*

#### **The Vietnamese experience with CRP testing in the community setting**

*Nga Do Thi Thuy (Ha Noi, Viet Nam)*

#### **The Nigerian experience with CRP testing in the community setting**

*Augustine Onwunduba (Awka, Nigeria)*

#### **CRP testing in diagnosing tuberculosis in Zambia and South Africa**

*TBA*

#### **The health economics of CRP testing in LMICs**

*Yoel Lubell (Bangkok, Thailand)*

## 2-hour Symposium

### **Faecal microbiota transplantation and live biotherapeutic products: scientific and regulatory challenges**

#### **Chairs:**

*Ed Kuijper (Leiden, Netherlands)*

*Lindsey Edwards (London, United Kingdom)*

#### **How can we recognise and deal with adverse events of Faecal Microbiota Transplantation?**

*Serena Porcari (Rome, Italy)*

#### **What to check? An attempt at evidence-based donor screening**

*Elisabeth Terveer (Leiden, Netherlands)*

#### **What are the right bugs – Developing LBPs out of FMTs**

*Lena Biehl (Cologne, Germany)*

#### **What's up next? – Hot LBP candidates**

*Ilan Youngster (Beer Yaakov, Israel)*

**Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), The European Faecal Microbiota Transplantation Network of academics (EurFMT), European Helicobacter & Microbiota Study Group (EHMSG)**

## 2-hour Symposium

## Precision genomics to improve infectious diseases management

### Chairs:

*Jacob Moran-Gilad (Beer Sheva, Israel)*

*Ruth Massey (Cork, Ireland)*

### Using human genetics to understand causal inference in infection

*Gus Hamilton (Bristol, United Kingdom)*

### Applying bacterial GWAS to uncover new mechanisms of antibiotic resistance

*TBA*

### Evolution in action: large-scale within-host evolution analyses of persistent bacterial infections

*Stefano Giulieri (Melbourne, Australia)*

### Machine learning in bacterial genomics and metagenomics

*Francesco Asnicar (Trento, Italy)*

## 2-hour Symposium

### Enhancing efficiency and reducing cost in microbiological diagnostics using pool testing

#### Chairs:

*TBA*

*TBA*

### Congenital cytomegalovirus detection by pool testing in saliva

*Giannina Izquierdo (Santiago, Chile)*

### Detection of blood-borne pathogens in asymptomatic blood donors by pool testing

*Patricia Alvarez (Rio de Janeiro, Brazil)*

### Large-scale pooled testing to increase rapid molecular diagnostic test coverage for tuberculosis

*Melissa Sander (Bamenda, Cameroon)*

### Pool testing for screening of bacterial sexually transmitted infections

*TBA*

2-hour Symposium

**Novel strategies for eliminating the ‘worst films ever’**

**Chairs:**

*Markus Zeitlinger (Vienna, Austria)*

*Elisa Borghi (Milan, Italy)*

**What answers can biofilm PK/PD modelling provide?**

*Coen van Hasselt (Leiden, Netherlands)*

**subMIC antibiotic effects to improve biofilm PK/PD parameters – still relevant?**

*Francoise Van Bambeke (Brussels, Belgium)*

**PK/PD-based optimisation of antibiotic treatments to suppress resistance in dynamic biofilm models**

*Maria Dolores Macia (Palma De Mallorca, Spain)*

**Giving antibiotics an upper hand in the treatment of biofilm infections – antibiotic augmenting strategies**

*Claus Moser (Copenhagen, Denmark)*

**Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Scientific Affairs Subcommittee**

2-hour Symposium

**Proxy indicators: bridging the gap between surveillance and antimicrobial stewardship**

**Chairs:**

*Bhanu Sinha (Groningen, Netherlands)*

*TBA*

**A broad spectrum of possibilities: spectrum scores as a unifying metric**

*Céline Pulcini (Nancy, France)*

**Proxy indicators to estimate appropriateness of antibiotic prescriptions**

*Diane Ashiru-Oredope (London, United Kingdom)*

**How to bridge the gap between surveillance and antimicrobial stewardship**

*Mark G. J. De Boer (Leiden, Netherlands)*

**Health economics, surveillance and antimicrobial stewardship**

*Nina Zhu (London, United Kingdom)*

**Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID Education Subcommittee, International Society for Infectious Diseases (ISID)**

2-hour Symposium

**PK/PD to avoid emergence of resistance?**

**Chairs:**

*Anne-Grete Märtson (Leiden, Netherlands)*

*Joseph Meletiadis (Athens, Greece)*

**PK/PD and antibacterial therapy**

*Dolors Soy (Barcelona, Spain)*

**PK/PD and antifungal therapy**

*Roger Brüggemann (Nijmegen, Netherlands)*

**PK/PD and antiviral therapy**

*Joseph Standing (London, United Kingdom)*

**PK/PD considerations in anthelmintic treatment**

*Jennifer Keiser (Basel, Switzerland)*

2-hour Symposium

**New insights into *Candida* pathogenesis**

**Chairs:**

*Aleksandra Barac (Belgrade, Serbia)*

*Josh Nosanchuk (New York, United States)*

**Insights into the evolution of *Candida* under antifungal pressure**

*Attila Gacser (Szeged, Hungary)*

**How do *Candida* extracellular vesicles modify virulence during disease?**

*Leonardo Nimrichter (Rio De Janeiro, Brazil)*

**The commensal to pathogen transition: kind to killer**

*Ilse Jacobsen (Jena, Germany)*

**Fungal-bacterial interactions: who wins?**

*Rebecca Hall (Kent, United Kingdom)*



2-hour Symposium

**Survival of the parasites: is treatment failure due to antimicrobial resistance?**

**Chairs:**

*Jaco Verweij (Tilburg, Netherlands)*

*Hanne Brekke (Oslo, Norway)*

**Nitroimidazole refractory *Giardia* infection**

*Pavla Tumova (Prague, Czech Republic)*

**Treatment failure in scabies**

*Francisco Bravo (Lima, Peru)*

**Recurrent *Enterobius* infections**

*Sarah Eisen (London, United Kingdom)*

**Recent advances in the treatment of visceral leishmaniasis and PKDL**

*Shyam Sundar (Varanasi, India)*

**Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)**

2-hour Symposium

**Unveiling the challenges: nosocomial infections in ECMO-supported patients**

**Chairs:**

*Antonios Katsounas (Bochum, Germany)*

*Jordi Riera (Barcelona, Spain)*

**Source of infection and pathogens**

*Christian Eckmann (Hannover, Germany)*

**Prophylaxis and empiric treatment**

*Giacomo Grasselli (Milan, Italy)*

**Diagnostic criteria and definitions**

*Graeme MacLaren (Singapore, Singapore)*

**Microbial films**

*Marta Hernández-Meneses (Barcelona, Spain)*

**Co-organised with: European Extracorporeal Life Support Organization**

2-hour Symposium

**Challenges in infection management, prevention and antimicrobial stewardship in long-term care facilities**

**Chairs:**

*Giusy Tiseo (Pisa, Italy)*

*TBA*

**The burden of nosocomial infections in long-term facilities**

*Virginie Prendki (Geneva, Switzerland)*

**Pneumonia in the elderly: management and prevention**

*TBA*

**Challenges in the clinical diagnosis of infection in the elderly**

*Maheen Abidi (Aurora, United Kingdom)*

**Challenges in implementing antimicrobial stewardship in long-term care facilities**

*Elena Carrara (Verona, Italy)*

**Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee)**

2-hour Symposium

**Endoscopy: infection risks and mitigation**

**Chairs:**

*TBA*

*TBA*

**Should we be concerned about infection by contaminated endoscopes**

*TBA*

**Microbial surveillance of endoscopes; any standardisation to be expected?**

*TBA*

**Understanding the causes of medical device contamination: it is all biofilm!**

*Roberto Rusconi (Milan, Italy)*

**Does the European medical Device Regulation bring us safer duodenoscopes?**

*TBA*

**Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)**

2-hour Symposium

**Difficile to treat: advanced management strategies in difficult to treat CDI**

**Chairs:**

*Frédéric Barbut (Paris, France)*

*Kerrie Davies (Leeds, United Kingdom)*

**Severe CDI: when standard protocols fail**

*TBA*

**Therapies for complicated CDI**

*Emma Jane Bishop (Melbourne, Australia)*

**Recurrent CDI: breaking the cycle**

*Andrea Marino (Catania, Italy)*

**Live biotherapeutic products for *Clostridioides difficile* infection**

*Simon Goldenberg (London, United Kingdom)*

**Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)**

2-hour Symposium

**Single-cell approaches to dissect cellular phenotypic heterogeneity of bacterial pathogen populations**

**Chairs:**

*Annelies Zinkernagel (Zurich, Switzerland)*

*Christian Stephan Lentz (Tromsø, Norway)*

**The relevance of cellular phenotypic heterogeneity for bacterial virulence and survival**

*TBA*

**Single-cell imaging and heterogeneity in antimicrobial resistance**

*Stefano Pagliara (Exeter, United Kingdom)*

**Single-cell RNAseq and heterogeneity in bacterial transcription**

*Anna Kuchina (Seattle, United States)*

**Dissecting the function of individual bacteria in their spatial context**

*TBA*

## 2-hour Symposium

### Breaking new ground in febrile neutropaenia management

#### Chairs:

*Murat Akova (Ankara, Turkey)*

*Monica Slavin (Melbourne, Australia)*

#### Do we need to redefine the concept of febrile neutropaenia in the era of immunotherapy?

*Manuela Aguilar-Guisado (Seville, Spain)*

#### Should some patients be empirically treated with combination therapy?

*Dina Averbuch (Jerusalem, Israel)*

#### Role of new antibiotics in febrile neutropaenia

*Malgorzata Mikulska (Genoa, Italy)*

#### Can treatment strategies be personalised using AI or new diagnostic tools?

*Carolina Garcia Vidal (Barcelona, Spain)*

**Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), European Conference on Infections in Leukemia (ECIL)**

## 2-hour Symposium

### To screen or not to screen prior to transplant?

#### Chairs:

*Oscar Len (Barcelona, Spain)*

*Laura Barcan (Buenos Aires, Argentina)*

#### HHV-8 Screening

*Alessandra Mularoni (Palermo, Italy)*

#### TB screening and prevention in endemic regions

*Rubina Naqvi (Karachi, Pakistan)*

#### Screening for and prevention of chagas in immunocompromised hosts

*Marcelo Radisci (Buenos Aires, Argentina)*

#### Screening of lung donors for mollicutes

*Michael Ison (Derwood, United States)*

2-hour Symposium

**Out of the spotlight or out of reach? Vaccination of hard-to-reach groups**

**Chairs:**

*TBA*

*Justyna Kowalska (Warsaw, Poland)*

**Ukrainian war refugees and vaccination attitudes: experience from Poland**

*Maria Gańczak (Zielona Góra, Poland)*

**Vaccination in migrants in Latin America: the challenges of transit through Darien, Panama**

*Alfonso J. Rodriguez-Morales (Pereira, Colombia)*

**Are penitentiary systems ready for introducing vaccination programmes?**

*Lara Tivoschi (Pisa, Italy)*

**HPV and other essential vaccinations for sex workers**

*Deborah Konopnicki (Brussels, Belgium)*

**Co-organised with: ESCMID Vaccine Study Group (EVASG)**

2-hour Symposium

**Diphtheria: from re-emergence to vaccine strategies**

**Chairs:**

*TBA*

*Julie Toubiana (Paris, France)*

**Diphtheria: from clinical picture to medical management**

*Regina Oladokun (Ibadan, Nigeria)*

**The epidemiology of diphtheria worldwide over the last half-century: more than one comeback**

*Andreas Hoefler (Solna, Sweden)*

**There's more than one toxigenic *Corynebacterium*: the current genomics landscape of diphtheria-associated strains**

*Sylvain Brisse (Paris, France)*

**Diphtheria vaccination: a reappraisal**

*Gayatri Amirthalingam (London, United Kingdom)*

**Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Vaccine Study Group (EVASG)**

2-hour Symposium

**Climate change: changing risks and adaptation strategies for a world on the move**

**Chairs:**

*TBA*

*Rachel Lowe (Barcelona, Spain)*

**Vector-borne diseases in Europe and clinical consequences**

*Tuba Dal (Ankara, Turkey)*

**Rising temperatures and risks of fungal disease**

*Anuradha Chowdhary (New Delhi, India)*

**Strategies for climate prevention and adaptation in a moving world**

*TBA*

**AMR in climate change-affected countries**

*Esmita Charani (London, United Kingdom)*

**Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)**

2-hour Symposium

**The quality of antibiotics used in the communities of LMICs**

**Chairs:**

*TBA*

*Thi Thuy Ngo Do (Hanoi, Vietnam)*

**The quality of antibiotics and their potential impact on patient outcome and AMR**

*Paul Newton (Oxford, United Kingdom)*

**Quality of common antibiotics in two sub-Saharan countries**

*TBA*

**Encountered challenges and reflections on conducting multi-country medicine quality studies**

*Noudy Sengxeu (Vientiane, Lao People's Democratic Republic)*

**Confusion in appearance of common used antibiotics in LMICs**

*Heiman Wertheim (Nijmegen, Netherlands)*

2-hour Symposium

**Controlled human infection models**

**Chairs:**

*Frederick Hayden (Charlottesville, United States)*

*Nikolai Siemens (Greifswald, Germany)*

**Updates on the dengue human infection model**

*Kirsten Lyke (Baltimore, United States)*

**Controlled human infection models of streptococcal pharyngitis**

*TBA*

**Controlled human infection models of parasitic infections**

*Meta Roestenberg (Leiden, Netherlands)*

**Controlled human infection models of non-typhoidal Salmonella**

*Malick Gibani (London, United Kingdom)*

**Co-organised with: British Infection Association (BIA)**



# 1-hour Symposia

## 1-hour Symposium

### **Immune reconstitution syndrome in infectious diseases: Who. Are. You?**

#### **Chairs:**

*Justyna Kowalska (Warsaw, Poland)*

*TBA*

#### **IRIS in HIV immunocompromised hosts: a failure of success**

*Paola Cinque (Milan, Italy)*

#### **IRIS in non-HIV immunocompromised hosts: it is all about balance**

*TBA*

## 1-hour Symposium

### **Emerging infectious diseases: staying informed and prepared in a globalised world**

#### **Chairs:**

*Nitin Gupta (Manipal, India)*

*Pikka Jokelainen (Copenhagen, Denmark)*

#### **Lessons learnt from previous outbreaks**

*Marta Mora-Rillo (Madrid, Spain)*

#### **Disease X: preparedness for the next pandemic**

*Yee-Sin Leo (Singapore, Singapore)*

**Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.**

## 1-hour Symposium

### **Beat the cancer by beating the infections**

#### **Chairs:**

*Daniela Maric (Novi Sad, Serbia)*

*TBA*

#### **Prevention of infection-associated cancer: learning from each other**

*TBA*

#### **Test and treat early to prevent cancer: hepatitis B and hepatitis C**

*Francesco Negro (Geneva, Switzerland)*

1-hour Symposium

**Avian influenza in mammals: jumps under the radar**

**Chairs:**

*Ana Vale (Dublin, Ireland)*

*Patricia Antunes (Porto, Portugal)*

**Threat of highly pathogenic avian influenza to non-traditional hosts, including humans**

*Thijs Kuiken (Rotterdam, Netherlands)*

**Recent changes in the epidemiology of avian influenza in relation to human health risks**

*Ron Fouchier (Rotterdam, Netherlands)*

1-hour Symposium

**Diagnosing the undiagnosed fraction: the final step towards viral hepatitis elimination**

**Chairs:**

*Snjezana Zidovec Lepej (Zagreb, Croatia)*

*TBA*

**Role of reflex testing strategies in identifying patients with chronic viral hepatitis**

*Oana Săndulescu (Bucharest, Romania)*

**Management and elimination of hepatitis in hard-to-reach persons**

*Süda Tekin (Istanbul, Turkey)*

**Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Romanian Society for Infectious Diseases and HIV/AIDS 1-hour Symposium**

1-hour Symposium

**Sex differences in management and outcome of patients with serious bacterial infections**

**Chairs:**

*Merel Lambregts (Leiden, Netherlands)*

*Anna Norrby-Teglund (Huddinge, Sweden)*

**Sex impacts incidence, management, and outcome in bacteraemia**

*Erik Solligard (Trondheim, Norway)*

**The complex interplay between gender and sepsis**

*Ines Lakbar (Montpellier, France)*

**Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)**

1-hour Symposium

**Lyme neuroborreliosis: challenges in diagnosis and treatment**

**Chairs :**

*Alexandra Mailles (Saint-Maurice, France)*

*Joanna Maria Zajkowska (Bialystok, Poland)*

**Challenges in diagnosis of Lyme neuroborreliosis**

*Rick Dersch (Freiburg, Germany)*

**Challenges in treatment of Lyme neuroborreliosis**

*Anne Marit Solheim (Bergen, Norway)*

**Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR)**

1-hour Symposium

**Why is the concept of complicated UTI so complicated?**

**Chairs:**

*Gernot Bonkat (Basel, Switzerland)*

*Maeve Doyle (Waterford, Ireland)*

**The concept of complicated UTI: underlying conditions matter**

*Suzanne Geerlings (Amsterdam, Netherlands)*

**The concept of complicated UTI: the site of infection matters most**

*Jesús Rodríguez-Baño (Seville, Spain)*

**Co-organised with: ESCMID Education Subcommittee**

1-hour Symposium

**What happens following TB infection?**

**Chairs:**

*Catherine Ong (Singapore, Singapore)*

*Sean Wasserman (London, United Kingdom)*

**Post-TB disease: burden and treatment strategies**

*Deborah Chong (London, United Kingdom)*

**TB sequelae and fungal infection**

*Helmut Salzer (Linz, Austria)*

**Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), CPAnet**

1-hour Symposium

**How to manage bacterial meningitis in low resource settings**

**Chairs:**

*Christina Obiero (Kilifi, Kenya)*

*TBA*

**Bacterial meningitis diagnosis and surveillance**

*Divya Deodhar (Ludhiana, India)*

**Clinical presentation and management of CNS infections**

*Kartika Maharani (Jakarta, Indonesia)*

**Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Spanish Society of Forensic Pathologists (SEPAF)**

1-hour Symposium

**Predicting antibiotic susceptibility profiles from whole genome sequences: state-of-the-art**

**Chairs:**

*Balaji Veeraraghavan (Vellore, India)*

*Werner Ruppitsch (Vienna, Austria)*

**Impact of the WHO's developed catalogue of mutations on rapid TB diagnosis and treatment**

*Thomas Schön (Linköping, Sweden)*

**Antimicrobial resistance prediction using whole genome sequencing**

*TBA*

**Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers (ESGEM), EUCAST Steering Committee**

1-hour Symposium

**Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and therapeutic approach**

**Chairs:**

*Arjana Tambic (Zagreb, Croatia)*

*Robert A. Bonomo (Cleveland, United States)*

**Novel beta-lactams and beta-lactamase inhibitors: challenges for laboratory diagnostics**

*Anna Sramkova (Pilsen, Czech Republic)*

**Clinical perspectives of novel beta-lactams and beta-lactamase inhibitors**

*Parikshit Prayag (Pune, India)*

**Co-organised with: EUCAST Steering Committee**

1-hour Symposium

**People-centred approach to strengthening the AMR response at primary care**

**Chairs:**

*Benedikt Huttner (Geneva, Switzerland)*

*Mirfin Mpundu (Lusaka, Zambia)*

**Implementation of WHO's people-centred interventions**

*Nienke Bruinsma (Geneva, Switzerland)*

**Opportunities for strengthening AMR interventions in primary healthcare**

*TBA*

1-hour Symposium

**Farm to fork: food-borne antimicrobial resistance**

**Chairs :**

*Beatriz Guerra Román (Parma, Italy)*

*TBA*

**Foodborne risk in meat and fishery products and impact on AMR**

*Anders Dalsgaard (Frederiksberg, Denmark)*

**Control challenges associated with food-borne multidrug resistance**

*Luisa Peixe (Porto, Portugal)*

**Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG)**

1-hour Symposium

**Global clones and evolving resistance mechanisms towards newer beta-lactams: where are we heading?**

**Chairs:**

*Yeşim Beşli (Istanbul, Turkey)*

*Spyros Pournaras (Athens, Greece)*

**Carbapenems'-producing Enterobacterales: the not so good, the bad and the ugly**

*Arjana Tambic Andrasevic (Zagreb, Croatia)*

**The *P. aeruginosa* frightening cocktail: high-risk clones, horizontally-acquired resistance and evolving mutational resistome**

*Katy Jeannot (Besançon, France)*

**Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)**

1-hour Symposium

**Chronic infections in the era of CFTR modulators: what is going on in cystic fibrosis lungs these days?**

**Chairs:**

*Pavel Drevinek (Prague, Czech Republic)*

*Helle Krogh Johansen (Copenhagen, Denmark)*

**The lung microbiome of people with cystic fibrosis receiving modulator therapy**

*Sébastien Boutin (Kiel, Germany)*

**Infections in Cystic Fibrosis patient on modulator therapy: present and future**

*Alessandra Bragonzi (Milan, Italy)*

**Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society for Medical Microbiology**

1-hour Symposium

**Value-based syndromic diagnostics in medical microbiology: pro / con debate**

**Chairs:**

*Eric Claas (Leiden, Netherlands)*

*Hege Vangstein Aamot (Lorenskog, Norway)*

**Pro: clinical benefit and potential for improved patient outcomes**

*Kirsten Sørgaard (Aalborg, Denmark)*

**Con: limitations, costs, and possible overuse of syndromic panels**

*Gilbert Greub (Mollie-Margot, Switzerland)*

**Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française**

1-hour Symposium

**Impact on including a measure of viability in molecular diagnostic**

**Chairs:**

*TBA*

*FusunCan (Istanbul, Turkey)*

**Viability markers in support of development of *Chlamydia* screening recommendations**

*Petra Wolffs (Maastricht, Netherlands)*

**Measuring viability to improve the correlation of AMR markers and clinical outcomes in *Neisseria gonorrhoeae***

*Tatum Mortimer (Athens, United States)*

**Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)**

1-hour Symposium

**The challenge of a healthy microbiota in neonates**

**Chairs:**

*Maria Vehreschild (Frankfurt, Germany)*

*Walter Zingg (Zurich, Switzerland)*

**Infant gut microbiome development**

*Debby Bogaert (Edinburgh, United Kingdom)*

**Metagenomic signatures and antibiotic disruption of the gut microbiome in neonates**

*Gautam Dantas (St. Louis, United States)*

**Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), European Society of Paediatric Infectious Diseases (ESPID)**

1-hour Symposium

**Antimicrobial prescribing: myths or pearls?**

**Chairs:**

*TBA*

*TBA*

**Why treat IV when PO is possible?**

*TBA*

**De-escalation of antibiotic therapy to narrow-spectrum IV drugs**

*TBA*

**Co-organised with: CMI Communications Board of Editors, ESCMID AMR Action Subcommittee, ESCMID Study Group for Antimicrobial stewardship (ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Scientific Affairs Subcommittee**

1-hour Symposium

**PK/PD in drug development: what's in it for me?**

**Chairs:**

*Sebastian Wicha (Hamburg, Germany)*

*Sandrine Marchand (Poitiers, France)*

**PK/PD from the EUCAST/regulatory perspective: what tools do we need?**

*Joseph Meletiadis (Athens, Greece)*

**PK/PD for new anti-TB drugs**

*Elin Svensson (Uppsala, Sweden)*

**Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)**



1-hour Symposium

**Macrolides in community-acquired pneumonia: therapeutic necessity or path to overuse?**

**Chairs:**

*Marc Bonten (Utrecht, Netherlands)*

*TBA*

**Pro: maximising outcomes with evidence-based use**

*Evangelos Giamarellos-Bourboulis (Athens, Greece)*

**Con: the risks of routine (over)use**

*Aurélien Dinh (Garches, France)*

1-hour Symposium

**Probiotics in infectious diseases: current state-of-play**

**Chairs:**

*Nicolas Bénéch (Lyon, France)*

*TBA*

**Probiotics in infectious diseases: the perfect complement to antimicrobial therapies?**

*TBA*

**The horizon of next generation probiotics for infectious diseases**

*Cormac Gahan (Cork, Ireland)*

**Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)**

1-hour Symposium

**Antimicrobial stewardship across the lifespan from paediatrics to geriatrics**

**Chairs:**

*Christina Obiero (Kilifi, Kenya)*

*TBA*

**Antimicrobial Stewardship in paediatrics across different settings**

*Taylor Morrisette (Charleston, United States)*

**Stewardship in geriatrics: an exceedingly important target**

*Dafna Yahav (Ramat-Gan, Israel)*

1-hour Symposium

**Cutting edge methods in mycology**

**Chairs:**

*TBA*

*TBA*

**Imaging for diagnosing mycoses: focus on 18F-FDG PET/CT**

*Ana Fernández-Cruz (Madrid, Spain)*

**Exploring the intersection of fungal metagenomics and medical mycology**

*Marcus Teixeira (Brasilia, Brazil)*

**Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID Education Subcommittee, Medical Mycology Study Group (GEMICOMED) within the SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiology), ESCMID Study Group for Critically Ill Patients (ESGCIP), Società Italiana per la Terapia Antinfettiva**

1-hour Symposium

**Emerging fungal diseases in children: global challenges and approach to management**

**Chairs:**

*Andreas H. Groll (Munster, Germany)*

*TBA*

**Emerging fungal infections in immunocompromised and geographically exposed children**

*Laura Ferreras-Antolín (Exeter, United Kingdom)*

**Best available treatments and options for children in resource-limited settings**

*Fabianne Carlesse (Sao Paulo, Brazil)*

**Co-organised with: ESCMID Fungal Infection Study Group (EFISG), German-Speaking Mycological Society (DMykG)**

1-hour Symposium

**Echinococcosis: neglected but expanding**

**Chairs:**

*Daniel Grupel (Jerusalem, Israel)*

*Francesca Tamarozzi (Verona, Italy)*

**Expansion and diversity of cystic echinococcosis**

*Pedro Legua (Lima, Peru)*

**Management of echinococcosis: evidence, eminence and new developments**

*Beate Gruener (Ulm, Germany)*

**Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)**

1-hour Symposium

**Sleeping sickness and Chagas: a tale of the two trypanosomes**

**Chairs:**

*Irene Losada (Barcelona, Spain)*

*Hanne Brekke (Oslo, Norway)*

**Human African Trypanosomiasis: recent diagnostic and medical practices**

*Jean-Mathieu Bart (Conakry, Guinea)*

**American Trypanosomiasis: diagnosis, screening and management**

*TBA*

**Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)**

1-hour Symposium

**We need to talk about toilets...**

**Chairs:**

*Juliette Severin (Rotterdam, Netherlands)*

*TBA*

**Infection risks from sanitation engineering**

*Davey L. Jones (Bangor, United Kingdom)*

**Ventilation in toilets: how can we improve it?**

*Michael Gormley (Edinburgh, United Kingdom)*

**Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)**

1-hour Symposium

**How innovations of AMR and HAI surveillance systems help the clinical practice**

**Chairs:**

*Mandy Wootton (Cardiff, United Kingdom)*

*Pascal Astagneau (Paris, France)*

**The EUCAST system in surveillance of AMR**

*Sören G. Gatermann (Bochum, Germany)*

**Insights into developments in the surveillance of HAIs**

*Diamantis Plachouras (Solna, Sweden)*

**Co-organised with: EUCAST Steering Committee, EUCIC Steering Committee, European Centre for Disease Prevention and Control (ECDC)**

1-hour Symposium

**Infection prevention and control and intensive care: challenges and solutions**

**Chairs:**

*Antonios Katsounas (Bocum, Germany)*

*Claire Roger (Nimes, France)*

**Intensive care unit (ICU) and infection: two sides of a coin**

*Reto Schuepbach (Zurich, Switzerland)*

**Ventilator- associated pneumonia (VAP) and ICU environment: how can we improve practices?**

*Despoina Koulenti (London, United Kingdom)*

**Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), EUCIC Steering Committee**

1-hour Symposium

**How long should contact isolation precautions be continued?**

**Chairs:**

*Cansu Cimen (Oldenburg, Germany)*

*TBA*

**Contact isolation in patients with MDR organisms: why, when, where?**

*Gabriel Birgand (Nantes, France)*

**Is discontinuation of contact precautions associated with an increase in infections?**

*Daniel J. Diekema (Iowa City, United States)*

**ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee, Multidisciplinary Joint Committee Infection Control UEMS**

1-hour Symposium

**Personalised patient management and infection prevention: current evidence and future perspectives**

**Chairs:**

*Agnes Hajdu (Budapest, Hungary)*

*Iris K. Minichmayr (Vienna, Austria)*

**The dosing perspective: towards individualised treatment strategies**

*Thomas Tängdén (Uppsala, Sweden)*

**The infection control perspective: advancing patient-centred approaches**

*Alessia Savoldi (Verona, Italy)*

1-hour Symposium

**Targeted vs. standard perioperative prophylaxis in solid organ transplant with MDR Gram-negative colonisation**

**Chairs:**

*David van Duin (Chapel Hill, United States)*

*TBA*

**Standard prophylaxis**

*Maddalena Giannella (Bologna, Italy)*

**Targeted approaches**

*Maristela Freire (Sao Paulo, Brazil)*

**Co-organised with: European Association for the study of the liver (EASL)**

1-hour Symposium

**Innovating antimicrobial drug discovery and host-pathogen interaction studies using chemical biology**

**Chairs:**

*TBA*

*TBA*

**Bacterial PROTACs: do proteolysis-targeting degraders represent a viable strategy for new antimicrobials?**

*TBA*

**Chemical strategies to profile peptidoglycan recognition at the microbe-microbe-host interface**

*TBA*

1-hour Symposium

**Strain dynamics in determining gut microbial colonisation resistance**

**Chairs:**

*Silvio Daniel Brugger (Zurich, Switzerland)*

*Li Yang Hsu (Singapore, Singapore)*

**Investigating *Escherichia coli* strain dynamics with metagenomics**

*Ashlee Earl (Cambridge, United States)*

**Long-term colonisation dynamics of carbapenemase-producing Enterobacterales**

*Niranjan Nagarajan (Singapore, Singapore)*

1-hour Symposium

**New frontiers in bacterial pathogenesis**

**Chairs:**

*Silvio Daniel Brugger (Zurich, Switzerland)*

*Abdou Hachani (Melbourne, Australia)*

**Bacterial infections and cellular immunity**

*Charlotte Odendall (London, United Kingdom)*

**Immuno-metabolism in bacterial diseases**

*Tania Wong (Newark, United States)*

1-hour Symposium

**dsDNA virus infections in immunocompromised patients**

**Chairs:**

*TBA*

*TBA*

**Challenges of diagnosis: do we need to treat all patients with detectable dsDNA virus PCR?**

*Hans Hirsch (Basel, Switzerland)*

**The role of CRISPR-Cas9-edited antiviral T cells against dsDNA virus infections**

*TBA*

1-hour Symposium

**ESCMID guidelines for the vaccination of immunocompromised individuals: solid organ transplant recipients**

**Chairs:**

*Zitta Barrella Harboe (Hillerod, Denmark)*

*Elisa Cordero Matia (Sevilla, Spain)*

**Vaccination against respiratory pathogens**

*Albert Vollaard (Bilthoven, Netherlands)*

**Other vaccines**

*Olivier Epaulard (Grenoble, France)*

**Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Vaccine Study Group (EVASG)**

1-hour Symposium

**Top 10 papers in Infections in solid organ transplantation, hematopoietic cell transplantation and cellular therapy**

**Chairs:**

*Malgorzata Mikulska (Genoa, Italy)*

*Nicolas Mueller (Zurich, Switzerland)*

**Top 10 papers in infections in SOT**

*Patricia Munoz (Madrid, Spain)*

**Top 10 paper in infections in HCT and cellular therapy**

*Joshua Hill (Seattle, United States)*

1-hour Symposium

**How to address anti-science in our community?**

**Chairs:**

*Tyra Grove Krause (Copenhagen, Denmark)*

*TBA*

**The rise of anti-science: lessons for the future scientist**

*Marion Koopmans (Rotterdam, Netherlands)*

**Open science for public trust**

*Lisa Hansen (Vancouver, Canada)*

1-hour Symposium

**Immunosenescence and immune response to vaccination**

**Chairs:**

*Dafna Yahav (Ramat-Gan, Israel)*

*Petar Velikov (Tsukuba, Japan)*

**How immunosenescence impacts vaccine response**

*Andrea Cossarizza (Modena, Italy)*

**Strategies to tackle immunosenescence and improve immune response to vaccination in the elderly**

*Inna Ovsyannikova (Rochester, United States)*

**Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Vaccine Study Group (EVASG)**

1-hour Symposium

**Vaccines and antimicrobial resistance**

**Chairs:**

*Iva Butic (Zagreb, Croatia)*

*Zitta Barrella Harboe (Hillerod, Denmark)*

**The impact of current and future vaccines on AMR: from pneumococcal to COVID-19**

*TBA*

**Can vaccines against AMR be translated into policy?**

*TBA*

**Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG)**



1-hour Symposium

**Exploring children's role in infection spread**

**Chairs:**

*Sanjay Patel (Winchester, United Kingdom)*

*TBA*

**Are children really super-spreaders of respiratory viruses?**

*Emmanuel André (Leuven, Belgium)*

**Should schools be closed at the start of the next pandemic?**

*Vittoria Colizza (Paris, France)*

**Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)**

1-hour Symposium

**What's the role of infant and maternal immunisation for paediatric RSV prevention?**

**Chairs:**

*Joanne Langley (Halifax, Canada)*

*TBA*

**Pros and cons of passive infant immunisation with mAb before their first RSV season**

*Federico Martín-Torres (Santiago De Compostela, Spain)*

**Pros and cons of maternal vaccination in preventing severe RSV infections in infants**

*Anne Vergison (Luxembourg, Luxembourg)*

1-hour Symposium

**Developing guidelines with AI tools: are they ready for prime time?**

**Chairs:**

*TBA*

*TBA*

**The PROs and CONS of using AI tools for developing guidelines**

*Holger Schunemann (Hamilton, Canada)*

**AI in action: validated tools for speeding up your systematic reviews and how to use them**

*TBA*

**Co-organised with: ESCMID Guidelines Subcommittee**

1-hour Symposium

**Communicating (your) ID science for policy and societal impact**

**Chairs:**

*Leonard Leibovici (Petah-Tiqva, Israel)*

*Ines Steffens (Solna, Sweden)*

**Communicating to policy makers and for societal impact**

*Dora Szabo (Budapest, Hungary)*

**Communicating to the press and news media to reach out far and wide**

*TBA*

**Co-organised with: CMI Board of Editors**

# Meet-the-Expert

Meet-the-Expert

**PrEP in Europe: current gaps and solutions**

*Teymur Noori (Stockholm, Sweden)*

*Milosz Parczewski (Szczecin, Poland)*

**Co-organised with: European AIDS Clinical Society (EACS)**

Meet-the-Expert

**Long acting injectables to treat and prevent infections: an example from HIV field**

*Monica Gandhi (San Francisco, United States)*

*TBA*

Meet-the-Expert

**Can we stop vertical transmission of syphilis, HIV and hepatitis? regional experience**

*Ecaterina Noroc (Chisinau, Republic of Moldova)*

*Fakhriddin Nizamov (Almaty, Kazakhstan)*

**Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, United Nations International Children's Emergency Fund (UNICEF)**

Meet-the-Expert

**Timing of antimicrobials in sepsis and septic shock - the sooner the better?**

*Laura Evans (Seattle, United States)*

*Evangelos Giamarellos-Bourboulis (Athens, Greece)*

**Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)**

Meet-the-Expert

**Healthcare-associated CNS infections**

*Diederik van De Beek (Amsterdam, Netherlands)*

*Alexandra Mailles (Saint-Maurice, France)*

**Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)**

Meet-the-Expert

**Short regimens for treating drug-susceptible and drug-resistant tuberculosis: insights from guidelines**

*Daria Podlekareva (Copenhagen, Denmark)*

*Raquel Melo (Porto, Portugal)*

**Co-organised with: European Respiratory Society (ERS)**

Meet-the-Expert

**Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare**

*Jaime Esteban (Madrid, Spain)*

*Philippe Morand (Paris, France)*

**Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGII), ESCMID Study Group for Mycobacterial Infections (ESGMYC)**

Meet-the-Expert

**Children are not just small adults: interactive paediatric cases**

*Julie Toubiana (Paris, France)*

*Sanjay Patel (Winchester, United Kingdom)*

Meet-the-Expert

**How to interpret resistance patterns from antibiograms**

*Tommaso Giani (Florence, Italy)*

*Lorena Diaz (Santiago, Chile)*

Meet-the-Expert

**How to perform molecular surveillance of multidrug resistant bacteria**

*Martina Lengerova (Brno, Czech Republic)*

*Henrik Hasman (Copenhagen, Denmark)*

Meet-the-Expert

**Global AMR Policy after UNGA: what do we do now!**

*Gisela Robles Aguilar (Oxford, United Kingdom)*

*Michael Sharland (London, United Kingdom)*

**Co-organised with: ESCMID AMR Action Subcommittee**

Meet-the-Expert

**EUCAST: What's new in susceptibility testing**

*Erika Matuschek (Växjö, Sweden)*

*Rafael Canton (Madrid, Spain)*

**Co-organised with: EUCAST Steering Committee**

Meet-the-Expert

**Implementing AI in microbiological diagnostics: practical steps and quality control**

*Oliver Nolte (Zurich, Switzerland)*

*Jennifer Dien Bard (Los Angeles, United States)*

**Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)**

Meet-the-Expert

**Cut a long story short: choosing NGS platforms**

*Etienne Ruppe (Paris, France)*

*Stefan Green (Chicago, United States)*

Meet-the-Expert

**Bioinformatic tools from start to finish**

*Vitor Borges (Lisboa, Portugal)*

*Clare Sloggett (Melbourne, Australia)*

Meet-the-Expert

**Translation of gut microbiome data to clinical practice: a guide for clinicians**

*Aycan Gundogdu (Kayseri, Turkey)*

*Niranjan Nagarajan (Singapore, Singapore)*

**Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)**

Meet-the-Expert

**AI use in antimicrobial stewardship**

*Shruti Gohil (Irvine, United States)*

*TBA*

Meet-the-Expert

**Local antimicrobials for deep infections**

*Karolina Akinosoglou (Patra, Greece)*

*Pierre Tattevin (Rennes, France)*

**Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGII), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)**

Meet-the-Expert

**Untangling the web: antimicrobial dose adjustments in renal impairment**

*Claire Roger (Nimes, France)*

*Isabel Spriet (Leuven, Belgium)*

**Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)**

Meet-the-Expert

**Multidisciplinary management of bone and joint infections: is there a recipe for success?**

*Natividad Benito (Barcelona, Spain)*

*Tiziana Ascione (Napoli, Italy)*

**Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)**

Meet-the-Expert

**Fungal meningitis: recognition and current status of management**

*Olivier Lortholary (Paris, France)*

*Janis Blair (Phoenix, United States)*

Meet-the-Expert

**How to teach medical mycology**

*Katrien Lagrou (Leuven, Belgium)*

*Mihai Mares (Iasi, Romania)*

**Co-organised with: European Confederation of Medical Mycology (ECMM)**

Meet-the-Expert

**How to perform clinical trials in mycoses**

*Monica Slavin (Melbourne, Australia)*

*Nkechi Azie (Jersey City, United States)*

**Co-organised with: ESCMID Fungal Infection Study Group (EFISG)**

Meet-the-Expert

**Navigating travel medicine: expert tips for safe international travel**

*Sophie Schneitler (Saarland, Germany)*

*Andreas Neumayr (Basel, Switzerland)*

Meet-the-Expert

**How to manage and prevent travellers' diarrhoea**

*Tinja Laaveri (Helsinki, Finland)*

TBA

Meet-the-Expert

**How to diagnose and treat infectious complications in critically ill patients receiving ECMO support**

*Jordi Riera (Barcelona, Spain)*

*Giacomo Grasselli (Milan, Italy)*

Meet-the-Expert

**Orthopaedic implant infections: new approaches for improved outcomes**

*Trish Peel (Melbourne, Australia)*

TBA

**Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)**

Meet-the-Expert

**How to practise WHO Guidelines for the prevention of bloodstream infections and other intravascular catheter infections**

*Kushlani Jayatilleke (Battaramulla, Sri Lanka)*

*Walter Zingg (Zurich, Switzerland)*

Meet-the-Expert

**How antimicrobial tolerance impacts polymicrobial biofilm-associated infections**

*Hans Steenackers (Leuven, Belgium)*

TBA

Meet-the-Expert

**How to apply organoid models to study infectious disease**

*Jennifer Rohn (London, United Kingdom)*

TBA

Meet-the-Expert

**The older solid organ transplant recipient: between frailty, immunosenescence and infection**

*Maheen Abidi (Aurora, United States)*

TBA

**Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE)**

Meet-the-Expert

**Do we need antiviral stewardship in immunocompromised hosts? Role of cell-mediated immunity**

*Michelle Yong (Melbourne, Australia)*

*Genovefa Papanicolaou (New York, United States)*

Meet-the-Expert

**How to understand infectious disease risks in changing climates**

*Rachel Lowe (Barcelona, Spain)*

TBA

Meet-the-Expert

**How to use large language models and machine learning for improving One Health**

*Javier Fernández (Oviedo, Spain)*

TBA

**Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), Portuguese Society of Microbiology (SPM)**

Meet-the-Expert

**How to navigate risk communication in public health**

*Marius Gilbert (Brussels, Belgium)*

*Christina Rolfheim-Bye (Oslo, Norway)*

**Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM)**

Meet-the-Expert

**How to use citizen science for public health**

*Jani Sormunen (Tukku, Finland)*

*TBA*

**Co-organised with: European Centre for Disease Prevention and Control (ECDC)**

Meet-the-Expert

**How to make sense out of guidelines and scientific evidence**

*Luigia Scudeller (Pavia, Italy)*

*Blin Nagavci (Gjakove, Kosovo)*

**Co-organised with: ESCMID Guidelines Subcommittee**

Meet-the-Expert

**How to master conflict management and negotiation in healthcare**

*Esther Calbo (Barcelona, Spain)*

*Jan A.J.W. Kluytmans (Utrecht, Netherlands)*



# Educational Sessions

## Educational Session

### **An update on arboviral disease challenges**

#### **Chairs:**

*Anna Papa-Konidari (Thessaloniki, Greece)*

*Misa Korva (Ljubljana, Slovenia)*

#### **The global epidemiology of arboviral diseases**

*Chantal B.E.M. Reusken (Bilthoven, Netherlands)*

#### **Arboviral diseases transmitted by mosquitoes**

*Luisa Barzon (Padua, Italy)*

#### **Arboviral diseases transmitted by ticks**

*Joanna Maria Zajkowska (Białystok, Poland)*

#### **Arboviral diseases transmitted by sandflies**

*Rémi Charrel (Marseille, France)*

**Co-organised with: Polish Association of Epidemiologists and Infectiologists**

## Educational Session

### **RSV infections: diagnosis, surveillance and treatment in the advent of vaccines**

#### **Chairs:**

*TBA*

*TBA*

#### **Costs of RSV infection, compared to other respiratory viruses**

*Barbara Rath (Besancon, France)*

#### **Challenges of diagnostics in high and low-resource settings: how often do we miss RSV cases?**

*Cheryl Cohen (Witwatersrand, South Africa)*

#### **RSV surveillance in the EU/EEA in the vaccine era**

*Eva Broberg (Solna, Sweden)*

#### **RSV fusion inhibitors and monoclonals: current status and future developments**

*Peter Openshaw (London, United Kingdom)*

**Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)**

Educational Session

**Beyond the gift of life: viral infection during pregnancy**

**Chairs:**

*TBA*

*TBA*

**Hepatitis B during pregnancy: diagnosis, management and outcome**

*TBA*

**RSV and Influenza during pregnancy: management and outcome**

*TBA*

**Prenatal screening and prevention of congenital CMV: shifting concepts and consensus guideline**

*Marianne Leruez-Ville (Paris, France)*

**Novel methods of vaccine administration to newborns**

*TBA*

**Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Hepatology Association of SubSaharan Africa (GHASSA)**

Educational Session

**A hard nut to crack in HIV**

**Chairs:**

*Justyna Kowalska (Warsaw, Poland)*

*Yoav Keynan (Winnipeg, Manitoba, Canada)*

**Viral reservoir: what a physician should know**

*Ivailo Alexiev (Sofia, Bulgaria)*

**Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians**

*Jose Arribas (Madrid, Spain)*

**Chronic vascular and pulmonary disease and HIV: what can we do about it?**

*Susanne Dam Nielsen (Copenhagen, Denmark)*

**Opportunistic infections: most common and most deadly**

*Milena Stevanovikj (Skopje, North Macedonia)*

**Co-organised with: Euroguidelines in Central and Eastern Europe Network Group**

Educational Session

**New guidelines for management of brain infections**

**Chairs:**

*Jacob Bodilsen (Aalborg, Denmark)*

*Kartika Maharani (Jakarta, Indonesia)*

**Tuberculous meningitis: what can we learn from the first global guidelines?**

*Joseph Donovan (London, United Kingdom)*

**WHO guidelines on bacterial meningitis: change of clinical practice?**

*TBA*

**ESCMID encephalitis guidelines 2024: what's new?**

*Tom Solomon (Liverpool, United Kingdom)*

**WHO guidelines for cryptococcal meningitis: success stories and barriers to implementation**

*Nelesh Govender (Johannesburg, South Africa)*

**Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)**

Educational Session

**Are urinary tract infections still the same?**

**Chairs:**

*Agnes Sonnevend (Pécs, Hungary)*

*François Caron (Rouen, France)*

**Pathogenesis of UTI in males and females**

*TBA*

**Diagnosis and treatment of UTI in the era of antimicrobial resistance**

*Jennifer Kranz (Aachen, Germany)*

**Can UTI be prevented?**

*TBA*

**Fungal and parasitic infections of the urinary tract**

*Gladys Mbwanji (Mwanza, United Republic of Tanzania)*

Educational Session

**Traumatic wound infections: diagnosis and treatment options**

**Chairs:**

*TBA*

*TBA*

**Multidrug-resistant infections after trauma in warzone**

*Shehan Hettiaratchy (Kyiv, Ukraine)*

**Fungal infections during natural disasters**

*Anuradha Chowdhary (New Delhi, India)*

**Bacteriophage therapy for multidrug-resistant wound infections in trauma**

*Tristan Ferry (Lyon, France)*

**Infection of burn wounds**

*Nur Benzonana (Istanbul, Turkey)*

**Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), Sociedad Española Enfermedades Infecciosas Microbiología Clínica (SEIMC), International Society of Antimicrobial Chemotherapy (ISAC)**

Educational Session

**New tools in acute bacterial infections and sepsis: from machine learning to precision medicine**

**Chairs:**

*Rita Murri (Rome, Italy)*

*Benjamin Mcfadden (Perth, Australia)*

**Differentiating acute infection, sepsis and sepsis mimics in the ED?**

*Lisa Mellhammar (Lund, Sweden)*

**Machine learning for early recognition of sepsis**

*Karsten Bogwardt (Zurich, Switzerland)*

**How to avoid common mistakes in randomised clinical study design**

*Mo Yin (Singapore, Singapore)*

**Improved clinical trials in community-acquired pneumonia using precision medicine**

*Lennie Derde (Utrecht, Netherlands)*

**Co-organised with: ESCMID Scientific Affairs Subcommittee, European Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), ESCMID Study Group for Antimicrobial stewardship (ESGAP), ESCMID Study Group for Mycobacterial Infections (ESGMYC)**

Educational Session

**This bacterium might harbour AmpC, what should I do?!**

**Chairs:**

*Pranita Tamma (Ellicott City, United States)*

*TBA*

**Laboratory identification of AmpC and its impact on *in vitro* resistance**

*Ana Gales (Sao Paulo, Brazil)*

**Divergent levels of AmpC expression in Gram-negative pathogens**

*Antonio Oliver (Palma De Mallorca, Spain)*

**Novel antimicrobials active against AmpC: what RCTs tell us in support of their use?**

*Amy Mathers (Charlottesville, United States)*

**Rational choice of antimicrobial therapy against AmpC-producing pathogens**

*Patrick Harris (Brisbane, Australia)*

Educational Session

**AMR surveillance: current challenges and new perspectives**

**Chairs:**

*Lina Cavaco (Copenhagen, Denmark)*

*Tomislav Mestrovic (Zagreb, Croatia)*

**The essentials of GRAM project: data sources, methodology and challenges in estimating AMR burden**

*Authia Gray (Seattle, United States)*

**Networks for surveillance of AMR in animal pathogens**

*Lucie Collineau (Maisons-Alfort, France)*

**Transition to genomic-based methodology for surveillance and outbreak detection to effectively combat AMR**

*Camilla Wiuff Coia (Copenhagen, Denmark)*

**Implementing and running hospital-wide genomic surveillance of pathogens**

*Alexander Mellmann (Münster, Germany)*

**Co-organised with: ESCMID AMR Action Subcommittee, ESCMID Education Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Veterinary Microbiology (ESGVM)**

Educational Session

**EUCAST Educational Workshop**

**Chairs:**

*Alasdair MacGowan (Bristol, United Kingdom)*

*Marlene Amara (Versailles, France)*

**EUCAST update**

*Sören G. Gatermann (Bochum, Germany)*

**Setting clinical breakpoints, assessing evidence**

*Anouk Muller (The Hague, Netherlands)*

**Benzylpenicillin susceptibility testing of *S. pneumoniae* by disk diffusion**

*Gunnar Kahlmeter (Växjö, Sweden)*

**What to do when there are no breakpoints**

*Barbara Holzkecht (Copenhagen, Denmark)*

**Detection of resistance mechanisms**

*Christian Giske (Stockholm, Sweden)*

**Co-organised with: EUCAST Steering Committee**

Educational Session

**How can we infer and track plasmid outbreaks?**

**Chairs:**

*Jacob Moran-Gilad (Beer Sheva, Israel)*

*Alessandra Carattoli (Rome, Italy)*

**New typing schemes for plasmids**

*Anita Schurch (Utrecht, Netherlands)*

**How plasmids shape the emergence of nosocomial pathogens**

*TBA*

**Understanding the complexity of plasmid outbreaks using bioinformatics**

*Torsten Seeman (Melbourne, Australia)*

**Plasmid transmission at the One Health interface**

*Nicole Stoesser (Oxford, United Kingdom)*

**Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM)**

Educational Session

**Implementing metagenomics in my lab and mistakes to avoid**

**Chairs:**

*Claudio Neidhoefer (Bonn, Germany)*

*Hege Vangstein Aamot (Lorenskog, Norway)*

**Is metagenomics right for my lab?**

*Paula Mölling (Örebro, Sweden)*

**Understanding the experimental and certification aspects of metagenomics**

*Mads Albertsen (Aalborg, Denmark)*

**Navigating tools, techniques, and procurement**

*Basil Britto Xavier (Antwerp, Belgium)*

**Setting realistic goals and outcomes for metagenomics integration**

*Claire Bertelli (Lausanne, Switzerland)*

**Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee**

Educational Session

**Challenges in identification and relevance of slow-growing pathogens**

**Chairs:**

*Karrie Davies (Leeds, United Kingdom)*

*TBA*

**Sampling and culturing anaerobes**

*Hugo Cruz (Porto, Portugal)*

**I have an anaerobe: what is it and does it matter?**

*Kathleen Boiten (Groningen, Netherlands)*

**Actinomyces in clinical samples: when is it worth the trouble?**

*Eija Inkeri Könönen (Turku, Finland)*

**Nocardiosis: when to test and how to manage results?**

*David Lebeaux (Paris, France)*

**Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Clostridioides difficile (ESGCD)**

Educational Session

**Demystifying pharmacokinetics and population pharmacokinetics: a toolkit for non-experts**

**Chairs:**

*João Paulo Telles (Sao Paulo, Brazil)*

*TBA*

**Pharmacokinetics 101: navigating the basics for optimal dosing**

*Linda Aulin (Leiden, Netherlands)*

**The ABCs of population pharmacokinetic models**

*Erwin Dreesen (Leuven, Belgium)*

**Looking into the crystal ball: exploring the fabulous world of PK-PD simulations**

*Vincent Aranzana-Climent (Poitiers, France)*

**Decoding population pharmacokinetic papers: interpreting, comparing and discussing results**

*Iris K. Minichmayr (Vienna, Austria)*

**Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)**

Educational Session

**OPAT: from aged wine to new vintage**

**Chairs:**

*Birgit Koch (Rotterdam, Netherlands)*

*Sonia Luque (Barcelona, Spain)*

**OPAT: principles, practice and checklists**

*Charlotte Quintens (Leuven, Belgium)*

**COPAT: complex outpatient parenteral antimicrobial therapy**

*Ronald Andrew Seaton (Glasgow, United Kingdom)*

**Antimicrobial stability and other challenges for OPAT practice?**

*Mark Gilchrist (London, United Kingdom)*

**New OPAT safety and efficacy data to guide practice**

*Matthew Rawlins (Murdoch, Australia)*

**Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), Society of Infectious Diseases Pharmacists (SIDP)**



Educational Session

**Going Viral! Phage therapy clinical rounds**

**Chairs:**

*Ameneh Khatami (Sydney, Australia)*

*Gregory German (Toronto, Canada)*

**Clinical cases and lessons from the STAMP protocol**

*Holly Sinclair (New South Wales, Australia)*

**Difficult cases treated with phages**

*Ghady Haidar (Pittsburgh, United States)*

**Challenging osteoarticular cases treated with phages**

*Tristan Ferry (Lyon, France)*

**Treating urinary tract infections with phages: dream or reality?**

*Saima Aslam (San Diego, United States)*

**Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)**

Educational Session

**New insights into antifungal agents and resistance**

**Chairs :**

*Jon Salmanton Garcia (Cologne, Germany)*

*Anuradha Chowdhary (New Delhi, India)*

**Emerging resistance in *Candida tropicalis***

*Sharon Chen (Sydney, Australia)*

**Mechanisms of resistance in *Candida glabrata***

*David Perlin (Nutley, United States)*

**Surveillance of resistance in *Aspergillus* species**

*Maiken Cavling Arendrup (Copenhagen, Denmark)*

**Environmental surveillance for antifungal resistance**

*Eveline Snelders (Wageningen, Netherlands)*

Educational Session

**Endemic mycoses and mycetoma: underdiagnosed and underreported fungal diseases**

**Chairs:**

*Rita Oladele (Lagos, Nigeria)*

*TBA*

**Global emergence and genetic diversity in histoplasmosis**

*TBA*

**Check in on Paracoccidioidomycosis**

*Beatriz Gomez (Bogotá, Colombia)*

**What is new in Talaromycosis**

*TBA*

**Mycetoma: treatment challenges of a unique neglected tropical disease**

*Borna Nyoake (Nairobi, Kenya)*

Educational Session

**Tropical dermatology: a case-based approach**

**Chairs:**

*Pedro Legua (Lima, Peru)*

*TBA*

**Parasitic diseases**

*TBA*

**Ectoparasites**

*M. Ramam (New Delhi, India)*

**Mycobacteria**

*Francisco Bravo (Lima, Peru)*

**Approach to rash in the returning traveller**

*Frank O. D. Pettersen (Oslo, Norway)*

Educational Session

**Diagnostic parasitology in the XXIst century: is microscopy “+” still useful?**

**Chairs:**

*Caroline Rönnberg (Stockholm, Sweden)*

*Miriam J. Álvarez-Martínez (Barcelona, Spain)*

**Artificial Intelligence for the diagnosis of parasitic infections**

*Bobbi Pritt (Rochester, United States)*

**Histopathology of parasitic infections**

*Richard Bradbury (Hobart, Australia)*

**Molecular diagnosis vs. microscopy in the diagnosis of parasitic infections**

*Sitara Sr Ajjampur (Vellore, India)*

**Paleoparasitology: what diagnostic tools?**

*Ayman El-Badry (Cairo, Egypt)*

**Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)**

Educational Session

**Malaria: when the drugs don't work management of treatment failure in non-endemic countries**

**Chairs:**

*TBA*

*TBA*

**Malaria in the non-endemic setting: who to treat as an outpatient and how to detect treatment failure**

*Emmanuel Bottieau (Antwerp, Belgium)*

**Malaria resistance mutations in the non-endemic setting: role of genomic surveillance**

*Anna Rosanas (Antwerp, Belgium)*

**How to manage Plasmodium Knowlesi infection**

*Giri Shan Rajahram (Kota Kinabalu, Malaysia)*

**Epidemiology and control of Plasmodium Knowlesi**

*Kimberly Fornace (Singapore, Singapore)*

**Co-organised with: British Infection Association (BIA)**

Educational Session

**How to detect, manage and communicate hospital outbreaks**

**Chairs:**

*Margaret Ip (Shatin, Hong Kong)*

*Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)*

**How to detect hospital outbreaks**

*David Fisman (Toronto, Canada)*

**How to confirm hospital outbreaks using genomics**

*John W. A. Rossen (Groningen, Netherlands)*

**How to rapidly respond to an ongoing hospital outbreak**

*Ermira Tartari (Geneva, Switzerland)*

**How to communicate hospital outbreaks via scientific publication**

*Ines Steffens (Solna, Sweden)*

Educational Session

**Surgical site infections: principles and practice in the era of multidrug resistance**

**Chairs:**

*Efthymia Giannitsioti (Athens, Greece)*

*Gabriel Birgand (Nantes, France)*

**Evolving antimicrobial resistance: do we need a change in surgical antimicrobial prophylaxis?**

*Camilla Rodrigues (Mumbai, India)*

**Role of decolonisation and bowel decontamination in regions of overwhelming multidrug resistance**

*Prasannakumar Palanikumar (Vellore, India)*

**Screening for MDR GNR colonisation: is there evidence for prophylaxis**

*Elisabeth Presterl (Vienna, Austria)*

**Perioperative prophylaxis in special populations in the era of MDR**

*Divyashree Shantamurthy (Navi Mumbai, India)*

Educational Session

**Best practices and emerging strategies in the management of ventilator- and healthcare-associated pneumonia**

**Chairs:**

*Jeroen Schouten (Nijmegen, Netherlands)*

*Fusun Can (Istanbul, Turkey)*

**Artificial Intelligence to predict VAP**

*Miia Jansson (Oulu, Finland)*

**Metagenomic approach to VAP diagnosis**

*Jacques Schrenzel (Geneva, Switzerland)*

**Viruses in VAP and HAP: should we worry about them?**

*Catia Cilloniz (Barcelona, Spain)*

**Optimising antibiotic therapy in VAP**

*Pinyo Rattanaumpawan (Bangkok, Thailand)*

Educational Session

**Primer on infection prevention and control: the crucial support by clinical microbiology**

**Chairs:**

*Margreet C. Vos (Groningen, Netherlands)*

*Elena Carrara (Verona, Italy)*

**Microbial fundamentals: building blocks of infection prevention and control**

*Laurence Armand-Lefevre (Paris, France)*

**Optimising environmental sampling in infection control: rational use of the microbiology laboratory**

*John E. Coia (Esbjerg, Denmark)*

**The crucial role of molecular typing in infection control**

*Stefanie Kampmeier (Würzburg, Germany)*

**How can we link diagnostic and antibiotic stewardship?**

*Constantinos Tsioutis (Nicosia, Cyprus)*

**Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee**

Educational Session

**Impact of diabetes on infectious diseases: what should we know?**

**Chairs:**

*Suzanne van Asten (Nijmegen, Netherlands)*

*Irene Andia Biraro (Kampala, Uganda)*

**The impact of diabetes and host-pathogen interaction and gut microbioma**

*Reinout van Crevel (Nijmegen, Netherlands)*

**Diabetes and invasive fungal infections**

*TBA*

**Viral infections and diabetes: is there a connection?**

*Malin Flodström-Tullberg (Stockholm, Sweden)*

**Pathogenesis of diabetic wound infection**

*TBA*

Educational Session

**Addressing infection challenges in immunocompromised patients: a case-based exploration**

**Chairs:**

*Asma Nasim (Karachi, Pakistan)*

*Maddalena Giannella (Bologna, Italy)*

**Challenges in managing gastrointestinal infections in patients with primary immunodeficiency**

*Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)*

**Respiratory infections in patients receiving CAR-T cells or bispecific monoclonal antibodies**

*TBA*

**Mycobacterial infections in patients with HIV infection**

*Graeme Ayton Meintjes (Cape Town, South Africa)*

**Breakthrough fungal infections in haematopoietic cancer and in stem cell transplantation**

*Dimitrios P. Kontoyiannis (Houston, United States)*

**Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)**

Educational Session

**Infections in cancer patients: tips for daily practice**

**Chairs:**

*José Molina Gil-Bermejo (Sevilla, Spain)*

*Stefan Schwartz (Berlin, Germany)*

**Tailoring pharmacologic prophylaxis in patients with non-haematologic cancer: from viruses to fungi**

*TBA*

**Pneumonitis or pneumonia? A practical approach to lung infiltrates in patients with solid tumours**

*TBA*

**The diagnostic dilemmas and treatment challenges of mycobacteria in cancer patients**

*Şiran Keske (Istanbul, Turkey)*

**HTLV-1 and T-cell lymphoma: predict and prevent**

*Lucy Cook (London, United Kingdom)*

**Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)**

Educational Session

**Vaccine hesitancy: from issues to solutions through developing communication skills**

**Chairs:**

*Monia Chemais (Soignies, Belgium)*

*Petar Velikov (Tsukuba, Japan)*

**Vaccine hesitancy and its consequences**

*Noni MacDonald (Halifax, Canada)*

**Why are patients and parents hesitant about vaccination?**

*TBA*

**Using social media to deal with vaccine hesitancy**

*Muge Cevik (Edinburgh, United Kingdom)*

**Strengthening vaccine confidence in patients and parents**

*TBA*

**Co-organised with: ESCMID Vaccine Study Group (EVASG)**

Educational Session

**The rare art of writing scientific articles: from conception to submission**

**Chairs:**

*Mical Paul (Haifa, Israel)*

*Marlieke De Kraker (Geneva, Switzerland)*

**Expressing yourself correctly: writing tips**

*Angela Huttner (Geneva, Switzerland)*

**Constructing your manuscript for an original article**

*Jesús Rodríguez-Baño (Seville, Spain)*

**The use of artificial intelligence tools for writing articles: what to do and not to do**

*Erlangga Yusuf (Antwerp, Belgium)*

**Selecting the best journal for my manuscript**

*Andre Kalil (Omaha, United States)*

**Co-organised with: CMI Board of Editors**

## Educational Session

### Tools for successful development as a medical educator

#### **Chairs:**

*Giorgia Caruana (Lausanne, Switzerland)*

*Joshua Nosanchuk (Bronx, United States)*

#### **Developing your educator professional identity**

*TBA*

#### **What do infection doctors need to learn to be prepared**

*TBA*

#### **Communities of practice: successful experience of a transformative collaboration and roadmap**

*Erin Bonura (Portland, United States)*

#### **The critical need for ongoing innovations in medical education**

*TBA*

**Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee, British Infection Association (BIA), Young Leader Circle of the American Society of Microbiology Educational Session**

## Educational Session

### Transforming your research idea into an appropriate study design

#### **Chairs :**

*Casandra Bulescu (Bucharest, Romania)*

*Mary Horgan (Dublin, Ireland)*

#### **Designing high-quality research studies: methodological skills and knowledge**

*Mical Paul (Haifa, Israel)*

#### **How to design and run scientific studies using AI agents as research assistants**

*Stefan Harrer (Melbourne, Australia)*

#### **Designing your first study: how to construct a workable project when your work environment may not help**

*Thomas Tängdén (Uppsala, Sweden)*

#### **Bridging early-career professionals with partners and seniors**

*Giorgia Caruana (Lausanne, Switzerland)*

**Co-organised with: CMI Board of Editors, CMI Communications Board of Editors, Trainee Association of ESCMID (TAE) Steering Committee Educational Session**



Educational Session

**The rules of the game: how to tackle the peer-review and publication process**

**Chairs:**

*TBA*

*Oana Sandulescu (Bucharest, Romania)*

**Communicating with journals, editors and reviewers**

*Angela Huttner (Geneva, Switzerland)*

**Publishing from LMICs: overcoming disparities**

*Mosepele Mosepele (Gaborone, Botswana)*

**The Wild West of predatory journals**

*Ursula Hofer (London, United Kingdom)*

**Communicating your publications on social media**

*Neil Stone (London, United Kingdom)*

**Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie, CMI Communications Board of Editors, ESCMID Parity Commission, CMI Board of Editors**

# Open Forum

Open Forum

## Vaccine rollout in low resource settings

**Chair:**

*Asma Nasim (Karachi, Pakistan)*

**Partially effective dengue vaccine: benefit versus potential harm**

*TBA*

**Introduction of malaria vaccines to countries in sub-Saharan Africa: acceptance and barriers**

*TBA*

**The story of COVID-19 vaccines in LMIC**

*Paul Adepoju (Ibadan, Nigeria)*

**Co-organised with: ESCMID Scientific Affairs Subcommittee, International Society of Antimicrobial Chemotherapy (ISAC)**

Open Forum

## Essential diagnostics in low-resource settings: why are we still talking?

**Chair:**

*Truls Michael Leegaard (Lorenskog, Norway)*

**Training skilled personnel in LMIC and brain drain: is the solution the problem?**

*Sipho Kenneth Dlamini (Observatory, South Africa)*

**Leveraging surveillance networks to strengthen basic bacteriology**

*Dissou Affolabi (Cotonou, Benin)*

**Microbial technologies to reverse societal inequalities and promote sustainability**

*TBA*

**Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch Society for Medical Microbiology (NVMM), ESCMID Parity Commission, Federation of European Microbiological Societies (FEMS), ESCMID Study Group for Antimicrobial Stewardship (ESGAP), Société belge d'Infectiologie**

Open Forum

**HIV: a global ethical conundrum**

**Chair:**

*Seif Al-Abri (Muscat, Oman)*

**HIV, from key population to general population: a Pandora's Box**

*Syed Faisal Mahmood (Karachi, Pakistan)*

**Ethical considerations in preventing mother-to-child HIV transmission**

*Glory Alexander (Bangalore, India)*

**HIV drug trials in Africa: ethical concerns**

*Reena Shah (Nairobi, Kenya)*

**Fighting Stigma of HIV**

*Teymur Noori (Stockholm, Sweden)*

**Co-organised with: ESCMID Ethics Advisory Committee (EEAC)**

Open Forum

**Science communication in a noisy world: podcasting and social media in ID/CM**

**Chair:**

*TBA*

**The ID:IOTS guide to creating a successful CM/ID podcast**

*Callum Mutch (Edinburgh, United Kingdom)*

**Using social media for CM/ID education**

*TBA*

**Podcasting and social media for antimicrobial stewardship and pharmacy**

*Erin McCreary (Pittsburgh, United States)*

**Co-organised with: CMI Communications Board of Editors**

Open Forum

**European CM/ID exam: going forward**

**Chair:**

*Siri Goepel (Tuebingen, Germany)*

**View from medical microbiology**

*Maeve Doyle (Waterford, Ireland)*

**View from infectious diseases**

*Eoghan De Barra (Dublin, Ireland)*

**View from trainees (TAE)**

*Christian Kraef (Copenhagen, Denmark)*

**European exam - how to prepare?**

*Annelies Verbon (Bosch En Duin, Netherlands)*

**Co-organised with: ESCMID Education Subcommittee, ESCMID Professional Affairs Subcommittee, UEMS Section of Medical Microbiology, UEMS Section of Infectious Diseases**

Open Forum

**Navigating the future of pandemics across One Health**

**Chair :**

*Xavier Lescure (Paris, France)*

**Status of the One Health Joint Plan of Action by the Quadripartite**

*Chadia Wannous (Paris, France)*

**National surveillance responsibilities under the updated international health regulations**

*TBA*

**Long-term consequences of emerging viral diseases**

*Alfonso J. Rodriguez-Morales (Pereira, Colombia)*

**Co-organised with: ESCMID Emerging Infections Subcommittee, ESCMID Study Group for Public Health Microbiology (ESGPHM), Trainee Association of ESCMID (TAE) Steering Committee, Brazilian Society of Infectious Diseases (SBI), Latin American Society for Travel Medicine**

Open Forum

**Predatory journals in CM/ID: from symptoms to cure**

**Chair:**

*Emily McDonald (Montreal, Canada)*

**The genesis of predatory journals: symptoms and root problems**

*Leonard Leibovici (Petah-Tiqva, Israel)*

**The role of editors and publishers of ‘reputable journals’: what can they do to stop predatory journals?**

*TBA*

**The roles of authors and academic institutions: towards governance and regulation**

*TBA*

**Co-organised with: CMI Communications Board of Editors**

Open Forum

**Diversity in CM and ID: gender gaps and policy traps**

**Chair:**

*André Fuchs (Stadtbergen, Germany)*

**How to avoid parity traps in ID/CM research?**

*TBA*

**Gender gaps in visibility at scientific conferences**

*Sarah Dellièrè (Paris, France)*

**Psychological determinants of empowerment at individual and societal level**

*TBA*

**Co-organised with: ESCMID Education Subcommittee, ESCMID Parity Commission**

# Year in Symposia

## 1-hour Symposium

### Year in public health

#### Chairs:

*Ziad Memish (Riyadh, Saudi Arabia)*

*Catherine Moore (Cardiff, United Kingdom)*

*Li Yang Hsu (Singapore, Singapore)*

*Rita Oladele (Lagos, Nigeria)*

## 1-hour Symposium

### Year in clinical microbiology

#### Chairs:

*Maurizio Sanguinetti (Rome, Italy)*

*TBA*

*Mario Ramirez (Lisbon, Portugal)*

*Anna Papa-Konidari (Thessaloniki, Greece)*

## 1-hour Symposium

### Year in infection control

#### Chairs:

*Nico Mutters (Bonn, Germany)*

*Ermira Tartari (Geneva, Switzerland)*

*Andrew James Stewardson (Victoria, Australia)*

*Kalisvar Marimuthu (Singapore, Singapore)*

## 1-hour Symposium

### Year in infectious diseases

#### Chairs:

*Evelina Tacconelli (Verona, Italy)*

*Nur Benzonana (Istanbul, Turkey)*

*Yoav Keynan (Winnipeg, Canada)*

*Elisa Cordero Matia (Seville, Spain)*